Auro Labs.

Which are the latest news on Auro Labs.?

Why is Auro Laboratories Ltd falling/rising?

As of 05-Sep, Auro Laboratories Ltd's stock price is at 256.90, reflecting a 0.73% increase and strong performance compared to the Sensex. The stock has risen 10.64% in the last week and shows positive investor sentiment, contributing to its upward trend.

As of 05-Sep, Auro Laboratories Ltd's stock price is rising, currently at 256.90, with a change of 1.85 (0.73%) increase. The stock has shown strong performance over various periods, outperforming the benchmark Sensex significantly. In the last week, the stock has risen by 10.64%, while the Sensex has decreased by 0.97%. Over the past month, Auro Laboratories has gained 7.11%, contrasting with a 2.44% decline in the Sensex.<BR><BR>Today, the stock has outperformed its sector by 1.02% and has been on a consecutive gain streak for the last three days, accumulating a total return of 12.2% during this period. It reached an intraday high of Rs 263.8, reflecting a 3.43% increase. Additionally, Auro Laboratories is trading above its moving averages for 5, 20, 50, 100, and 200 days, indicating a strong upward trend.<BR><BR>Investor participation has also increased, with a delivery volume of 16.09 k on September 3, which is up by 232.91% compared to the 5-day average. This rising interest suggests a positive sentiment among investors, contributing to the stock's upward movement. Overall, the combination of strong recent performance, positive investor sentiment, and favorable trading conditions are driving the rise in Auro Laboratories Ltd's stock price.

Who are in the management team of Auro Labs.?

The management team of Auro Labs includes Sharat Deorah (Chairman & Managing Director), Siddhartha Deorah and Kiran Kulkarni (Whole-time Directors), and several Independent Directors: Goverdhandas Aggarwal, Kailash Chandra Bubna, Kavita Vijayakant Sharma, and Vishal Kailash Chandra Jhunjhunwala, along with Sweta Agarwal as Company Secretary & Compliance Officer. They oversee the company's strategic direction and governance.

The management team of Auro Labs includes the following individuals:<BR><BR>1. **Sharat Deorah** - Chairman & Managing Director<BR>2. **Siddhartha Deorah** - Whole-time Director<BR>3. **Kiran Kulkarni** - Whole-time Director<BR>4. **Goverdhandas Aggarwal** - Independent Director<BR>5. **Kailash Chandra Bubna** - Independent Director<BR>6. **Kavita Vijayakant Sharma** - Independent Director<BR>7. **Vishal Kailash Chandra Jhunjhunwala** - Independent Director<BR>8. **Sweta Agarwal** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for the strategic direction and governance of the company.

What does Auro Labs. do?

Auro Laboratories Ltd is a micro-cap pharmaceutical company founded in 1992, specializing in generic Active Pharmaceutical Ingredients, particularly anti-diabetics like Metformin HCL. As of June 2026, it reported net sales of 9 Cr and a net profit of 1 Cr, with a market cap of INR 145 Cr.

Overview: <BR>Auro Laboratories Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of generic Active Pharmaceutical Ingredients (API), particularly Anti Diabetics like Metformin HCL.<BR><BR>History: <BR>Auro Laboratories Ltd was founded in 1992. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 145 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 31.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.33 <BR>Return on Equity: 10.32% <BR>Price to Book: 3.12 <BR><BR>Contact Details: <BR>Address: K-56 MIDC Indl Area, Tarapur Boisar Thane Maharashtra : 401506 <BR>Tel: 91-22-66635456 <BR>Email: auro@aurolabs.com <BR>Website: http://www.aurolabs.com

Who are the peers of the Auro Labs.?

Auro Labs. peers include Syschem (India), Achyut Healthcar, Smruthi Organic, Parnax Lab, Panch.Organics, Bal Pharma, Kimia Bioscien., and Quest Laborato. Auro Labs. has average management risk and a 1-year return of 13.69%, outperforming Syschem (India) but underperforming Guj. Inject(Ker) at 406.91%.

Peers: The peers of Auro Labs. are Syschem (India), Achyut Healthcar, Smruthi Organic, Parnax Lab, Panch.Organics, Bal Pharma, Kimia Bioscien., and Quest Laborato.<BR><BR>Quality Snapshot: Excellent management risk is observed at Parnax Lab and Quest Laborato, while Average management risk is found at Auro Labs., Bal Pharma, and Panch.Organics. Below Average management risk is present at Syschem (India), Achyut Healthcar, Smruthi Organic, and Kimia Bioscien. Good growth is noted at Syschem (India) and Parnax Lab, while Average growth is seen at Achyut Healthcar and Auro Labs., with Below Average growth at Smruthi Organic, Panch.Organics, Bal Pharma, Kimia Bioscien. and the rest. Excellent capital structure is held by Parnax Lab and Panch.Organics, while Good capital structure is noted at Syschem (India), Achyut Healthcar, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Guj. Inject(Ker) at 406.91%, while Syschem (India) has the lowest at -46.14%. Auro Labs. has a 1-year return of 13.69%, which is significantly higher than Syschem (India) but lower than Guj. Inject(Ker). Additionally, Syschem (India), Panch.Organics, Bal Pharma, Kimia Bioscien. have negative six-month returns.

How big is Auro Labs.?

As of 31st August, Auro Laboratories Ltd has a market capitalization of 145.00 Cr, with recent net sales of 14.71 Cr and a net profit of 0.97 Cr. Shareholder's funds are 46.35 Cr, and total assets amount to 121.08 Cr as of March 2026.

As of 31st August, Auro Laboratories Ltd has a market capitalization of 145.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Auro Laboratories Ltd reported Net Sales of 14.71 Cr and a Net Profit of 0.97 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 46.35 Cr and Total Assets of 121.08 Cr.

Should I buy, sell or hold Auro Laboratories Ltd?

When is the next results date for Auro Laboratories Ltd?

The next results date for Auro Laboratories Ltd is 14 August 2026.

The next results date for Auro Laboratories Ltd is scheduled for 14 August 2026.

Are Auro Laboratories Ltd latest results good or bad?

Auro Laboratories Ltd's latest Q2 FY26 results show a significant operational turnaround with a net profit of ₹0.72 crore and a 219.13% revenue increase. However, long-term challenges like declining sales, low return on equity, and a high P/E ratio suggest caution for investors.

Auro Laboratories Ltd's latest results for Q2 FY26 indicate a significant operational turnaround, showcasing both positive and concerning aspects. The company reported a net profit of ₹0.72 crore, marking a recovery from a loss in the previous quarter. Additionally, revenue surged by 219.13% quarter-on-quarter to ₹8.84 crore, which is a remarkable improvement.<BR><BR>The operating margin also improved dramatically to 26.70%, up from just 0.72% in Q1 FY26, reflecting better cost management and operational efficiency. However, despite these positive indicators, the company faces serious long-term challenges, including a five-year sales decline of -13.87% annually and a concerning return on equity (ROE) of only 10.30%, which is below the industry average.<BR><BR>Moreover, the company's high P/E ratio of 157.30x raises questions about its valuation, especially given the structural issues it faces. The elevated debt levels and minimal institutional interest further complicate the outlook.<BR><BR>In summary, while the latest quarterly results show a strong recovery, the underlying structural challenges and high valuation suggest caution for investors.

How has been the historical performance of Auro Labs.?

Auro Labs reported a net profit of 1.84 crore and total operating income of 19.40 crore for the year ending March 2025, with a profit after tax margin of 9.48% and an operating profit margin of 17.58%. Total liabilities increased to 99.10 crore, driven by long-term borrowings of 30.79 crore, while shareholder's funds grew to 42.97 crore.

Answer:<BR>The historical performance of Auro Labs shows a consolidated net profit of 1.84 crore for the year ending March 2025, with total operating income of 19.40 crore. The operating profit margin, excluding other income, stands at 17.58%, while the profit after tax margin is 9.48%. The company has total liabilities of 99.10 crore, with long-term borrowings increasing significantly to 30.79 crore from previous years. The total assets have also risen to 99.10 crore, reflecting growth in shareholder's funds, which reached 42.97 crore. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Auro Labs reported a total operating income of 19.40 crore, with a net profit of 1.84 crore, indicating a profit after tax margin of 9.48%. The operating profit, excluding other income, was 3.41 crore, leading to an operating profit margin of 17.58%. The company's total liabilities increased to 99.10 crore, driven by a rise in long-term borrowings to 30.79 crore. Shareholder's funds grew to 42.97 crore, supported by total reserves of 36.74 crore. The total assets also saw an increase, reaching 99.10 crore, while the cash flow from operating activities was reported at 5.00 crore, reflecting a net cash outflow of 1.00 crore for the year.

Is Auro Labs. overvalued or undervalued?

As of February 17, 2025, Auro Labs is considered very expensive and overvalued, with a PE Ratio of 113.15 and an EV to EBITDA of 60.60, significantly higher than its peers, despite a recent 1-year stock return of 35.93% compared to the Sensex's 7.60%.

As of 17 February 2025, Auro Labs has moved from an expensive to a very expensive valuation grade. The company is currently overvalued based on its financial metrics. Key ratios include a PE Ratio of 113.15, an EV to EBITDA of 60.60, and a Price to Book Value of 4.18, which significantly exceed those of its peers. For instance, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Divi's Lab shows a PE of 79.33 and an EV to EBITDA of 57.35, both indicating that Auro Labs is trading at a premium compared to these competitors.<BR><BR>In addition to its high valuation ratios, Auro Labs has a ROCE of 8.79% and a ROE of 3.69%, which do not justify its elevated price levels. The company has outperformed the Sensex in recent periods, with a 1-year stock return of 35.93% compared to the Sensex's 7.60%, yet this strong performance does not mitigate the overvaluation indicated by its financial ratios.

What is the technical trend for Auro Labs.?

As of May 13, 2025, Auro Labs has shifted to a bullish trend with strong indicators, including bullish MACD and Bollinger Bands on both weekly and monthly time frames, despite a mildly bearish KST signal, and has outperformed the Sensex with a 10.98% gain over the past week and 19.19% over the past month.

As of 13 May 2025, the technical trend for Auro Labs has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. The daily moving averages are bullish, reinforcing the positive outlook. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bullish stance on the monthly with no trend on the weekly. Overall, the strength of the bullish trend is supported by the recent price action, with the stock returning 10.98% over the past week and 19.19% over the past month, significantly outperforming the Sensex.

Who are the top shareholders of the Auro Labs.?

The top shareholders of Auro Labs include Auro Impex Private Ltd with 18.75%, individual investors with 36.57%, and Kirtilaben Jayantilal Mehta as the highest public shareholder at 3.13%. There are no pledged promoter holdings or foreign institutional investors, and mutual funds hold only 0.01%.

The top shareholders of Auro Labs include the promoters, with Auro Impex Private Ltd holding the largest stake at 18.75%. Additionally, individual investors collectively own 36.57% of the company. The highest public shareholder is Kirtilaben Jayantilal Mehta, who holds 3.13%. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved. Mutual funds have a minimal presence, with only one scheme holding 0.01%.

Has Auro Labs. declared dividend?

No Dividend History Available